Former Spark exec to lead a gene therapy upstart of his own; Big Pharma marketing vet named CEO of Swiss biotech
Peer Review had been wondering about La Barge’s next landing spot since he left Spark at the end of 2021. In his eight-year stretch with the gene therapy pioneer, he began as chief legal officer and was later promoted to CBO in 2019, when Spark was sold to Roche for $4.3 billion. Deerfield, where Greenwald is VP of business development, put up all the financing for Apertura’s $67 million Series A.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.